Sahm ScreenerSaudi Stock Screenerفلتر الأسهم السعودية
Home / Middle East Pharmaceutical Industries Co. / 2023 Annual Results

Middle East Pharmaceutical Industries Co. 2023 Annual Results

Revenue
SAR 338M
Net Profit
SAR 66M
EPS
SAR 3.29
Operating Cash Flow
SAR 93M

Middle East Pharmaceutical Industries Co. (4016) reported full year 2023 revenue of SAR 338M. Net profit came in at SAR 66M. Earnings per share were SAR 3.29. The company generated SAR 93M in operating cash flow. All figures sourced from CMA-mandated XBRL filings on the Saudi Exchange, processed by Sahm Screener.

Earnings Quality

Of every SAR 1.00 in reported net profit, SAR 1.41 arrived as operating cash flow — indicating Exceptional quality earnings with a cash conversion ratio of 1.41.

Key Financial Metrics

Metric2023
RevenueSAR 338M
Net ProfitSAR 66M
Net Margin19.4%
ROE21.5%
EPSSAR 3.29
Total AssetsSAR 445M
Total EquitySAR 306M
Total LiabilitiesSAR 138M
Operating Cash FlowSAR 93M
View full company profile →
View all years:
202520242023

Financial data sourced from CMA-mandated XBRL filings published on the Saudi Exchange (Tadawul). Data processed and structured by Sahm Screener (sahmscreener.com). Updated nightly. Last updated: 2024-03-25.